Match point

Cinedigm Selects Valossa Labs OY as its Video Artificial Intelligence (AI) Technology Partner for Cineverse, its Flagship Streaming Service

Retrieved on: 
Thursday, March 30, 2023

LOS ANGELES and OULU, Finland, March 30, 2023 /PRNewswire/ -- Cinedigm Corp. (NASDAQ: CIDM), the premier independent streaming entertainment company super-serving enthusiast audiences, today announced an agreement with Valossa Labs OY as its video Artificial Intelligence (AI) technology partner and vendor for its flagship streaming service Cineverse.

Key Points: 
  • LOS ANGELES and OULU, Finland, March 30, 2023 /PRNewswire/ -- Cinedigm Corp. (NASDAQ: CIDM), the premier independent streaming entertainment company super-serving enthusiast audiences, today announced an agreement with Valossa Labs OY as its video Artificial Intelligence (AI) technology partner and vendor for its flagship streaming service Cineverse.
  • The benefits of this technology are immense from a content programming, content discovery and targeted advertising perspective.
  • "We are proud to deliver our cutting-edge AI technology to Cinedigm, the premier independent streaming company in the US," noted Mika Rautiainen, CEO of Valossa Labs OY.
  • Our AI-assisted video solutions are establishing a new standard across the entertainment industry with a fast-growing number of international customers," says Rautiainen.

Cinedigm Partners with Influential Lifestyle Brand FUBU for Launch of the For Us By Us Network

Retrieved on: 
Monday, March 6, 2023

LOS ANGELES, March 6, 2023 /PRNewswire/ -- Cinedigm (NASDAQ: CIDM), the leading independent streaming company super-serving enthusiast audiences, today announced plans to become a premier provider of content tailored to the African American culture by entering a partnership with J. Alexander Martin, founder of the iconic fashion brand FUBU and successful producer Roberto "Rush" Evans, to launch the For Us By Us Network. The new service will feature high quality movies, authentic and raw content around issues, personalities and trends related to the hip-hop culture and lifestyle. The service will utilize Cinedigm's industry-leading Matchpoint technology platform to power the full service, making FUBU one of the first brands to leverage the Matchpoint platform on a SaaS basis.

Key Points: 
  • The new service will feature high quality movies, authentic and raw content around issues, personalities and trends related to the hip-hop culture and lifestyle.
  • The service will utilize Cinedigm's industry-leading Matchpoint technology platform to power the full service, making FUBU one of the first brands to leverage the Matchpoint platform on a SaaS basis.
  • The (FUBU) For Us By Us Network apps will be available across web, mobile as well as connected TV and will be powered by Cinedigm's Matchpoint Blueprint v2.0 platform.
  • "We created the For Us By Us Network so that we can provide high quality, positive content for our culture."

Chairman's Letter to Cinedigm Shareholders Outlines Stock Repurchase Program, Acquisition of Leading Faith and Family Streaming Properties and the Company's Future Outlook

Retrieved on: 
Thursday, March 2, 2023

Effective immediately , Cinedigm is implementing a stock repurchase program of up to 10 million shares.

Key Points: 
  • Effective immediately , Cinedigm is implementing a stock repurchase program of up to 10 million shares.
  • This gives us complete confidence that we can execute this significant stock repurchase program without hampering planned operating expenditures, such as key content acquisitions.
  • Most importantly, we believe that purchasing undervalued Cinedigm shares is a superb investment strategy for the Company.
  • This week, we announced the acquisition of two established faith and family media properties, Dove.org and Christian Cinema , from the Giving Company.

Cinedigm Appoints Marc Rashba as Executive Vice President, Partnerships

Retrieved on: 
Tuesday, January 3, 2023

LOS ANGELES, Jan. 3, 2023 /PRNewswire/ -- Cinedigm Corp. (NASDAQ: CIDM), a premier streaming technology and entertainment company super-serving enthusiast fan bases, today announced that it has hired Marc Rashba as Executive Vice President, Partnerships.

Key Points: 
  • LOS ANGELES, Jan. 3, 2023 /PRNewswire/ -- Cinedigm Corp. (NASDAQ: CIDM), a premier streaming technology and entertainment company super-serving enthusiast fan bases, today announced that it has hired Marc Rashba as Executive Vice President, Partnerships.
  • In this newly created role, he will oversee all facets of partnerships including cultivating and managing strategic partnerships, programming releases, negotiating agreements, expanding digital distribution and driving innovative new revenue opportunities.
  • His appointment is effective immediately and he'll report directly to Erick Opeka, Chief Strategy Officer, Cinedigm Corp & President of Cinedigm Networks.
  • Rashba also served as Vice President, Digital Partnerships & Development at Sony Pictures Entertainment as well as various global marketing roles for Sony prior to that for over 15 years.

Matchpoint Therapeutics Launches with $100 Million to Deliver on the Promise of Precision Covalent Medicines for Immune Diseases

Retrieved on: 
Friday, October 14, 2022

Matchpoint Therapeutics, a biotechnology company founded to leverage the power of covalency for the discovery of precision small molecule medicines, launched today with $100 million in financing.

Key Points: 
  • Matchpoint Therapeutics, a biotechnology company founded to leverage the power of covalency for the discovery of precision small molecule medicines, launched today with $100 million in financing.
  • The Series A follows a $30 million seed financing round co-led by Atlas Venture and Access Biotechnology in November 2021.
  • Matchpoint is pursuing genetically or clinically validated targets for which covalent chemistry is the only or best modality for therapeutic intervention.
  • Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses.